Company Overview
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -65.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -12.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -12.25% |
| 1 Year: | -65.54% |
Stock Price Performance
| 1 Year: | -97.08% |
| 6 Months: | -88.69% |
| 3 Months: | -69.50% |
| 1 Month: | -47.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.96 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -12.2% CAGR over 5 years.
- Trading 99.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELAB PMGC Holdings Inc. PHARMA | 4.85 | -0.00 | $3.93M | 0.00% | - | -105.22% | -12.25% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 432.12M | 142.82K | 316.53K | 554.65K | 614.56K | 605.53K | 527.48K | - | - | 285.95K | 681.99K |
| Gross Profit | 237.69M | 98.39K | 208.35K | 366.14K | 445.65K | 439.25K | 393.90K | - | - | 78.03K | 230.47K |
| Operating Income | - | -846.39K | -1.05M | -785.55K | -1.68M | -1.41M | -625.62K | - | - | -2.20M | - |
| Net Income | -499.08M | -1.08M | -1.28M | -783.05K | -1.40M | -1.41M | -1.50M | -1.61M | -562.36K | -2.59M | -4.97M |
| Diluted EPS | -0.05 | -0.11 | -0.13 | -0.08 | -0.08 | -0.08 | -0.07 | - | - | - | - |
| R&D Expense | 89.33M | 83.74K | 133.65K | 86.37K | 2.78K | 34.82K | 4.10K | 32.43K | 66.67K | 15.00K | 47.06K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 766.28K | 1.71M | - | 590.08K |
| Gross Profit | 447.31K | 1.13M | - | 185.31K |
| Net Income | -1.80M | -4.30M | -6.25M | -7.75M |
| Diluted EPS | -0.19 | -0.40 | - | - |
| R&D Expense | 228.75K | 7.41K | 104.65K | 147.01K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.89M | 5.19M | 8.99M | 12.87M |
| Total Equity | 450.63K | 1.13M | 3.83M | 6.66M | 7.84M |
| Cash & Equivalents | - | - | 3.33M | 3.98M | - |
| Total Liabilities | - | 760.87K | 1.36M | 2.33M | 5.03M |
| Current Liabilities | - | 588.27K | 1.30M | 1.80M | 3.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.59M | -4.56M | -5.49M | -5.93M |
| Investing Cash Flow | -32.03K | -11.19K | -610.56K | -2.77M |
| Financing Cash Flow | 2.36M | 6.74M | 6.76M | 10.12M |
| Capital Expenditure | - | -11.19K | -9.16K | -442.25K |
| Free Cash Flow | - | -4.57M | -5.50M | -6.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 58.4% | 66.2% | - | 31.4% |
| Operating Margin % | - | - | - | - |
| Net Margin % | -234.9% | -251.2% | - | -1,313.0% |
| ROE % | -159.1% | -112.4% | -93.8% | -98.9% |
| ROCE % | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 1.01% | 8.15K | $38.96K |
| 2 | Morgan Stanley | 0.65% | 5.30K | $25.33K |
| 3 | Vanguard Fiduciary Trust Co | 0.42% | 3.40K | $16.26K |
| 4 | Geode Capital Management, LLC | 0.30% | 2.41K | $11.51K |
| 5 | Citadel Advisors Llc | 0.26% | 2.07K | $9.89K |
| 6 | Vanguard Capital Management LLC | 0.21% | 1.67K | $7.97K |
| 7 | Virtu Financial LLC | 0.21% | 1.66K | $7.94K |
| 8 | Xtx Topco Ltd | 0.17% | 1.42K | $6.76K |
| 9 | Tower Research Capital LLC (TRC) | 0.03% | 251 | $1.20K |
| 10 | UBS Group AG | 0.03% | 235 | $1.12K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELAB
ELAB Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBiZU1ram1wNm4wOEtfQUQ5emluRUhNUVdzM1NqZkhjdTEwdzRaQVMyMHBSNk9keWdPMnVHMVZObW53d3c5QTRpLUVQbnRFQ2l6ekRZdjBDT0gzU21hMHln?oc=5" target="_blank">ELAB Stock Price, Quote & Chart</a>&nbs…
Why Is ELAB Stock Rising Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQVk03WVJ3T21Sc01vZ000R1Z6Tl9STHU3LWxEc2kxbzhRR2ZlWkJWNEpIWWVWMzg5b1l2Q2dYNEdydXYxcTR1ODJkM2NyNEt3MkVFVURrZVRYTUNLMEVMNy1GckhDd1M5LVJua2VIT0YtekloY3VCUDFLTjJYVkFWMU95RzkwX1MzVXBEbk…
Trading Systems Reacting to (ELAB) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNOGxyOE9MT3Z0ZkVIbjZIdUFlRnhYRmpuVTY3S20yd2Myd0VFNHQwbDJXMjhzWHRUdXNaeGVIczZfanlxY2pUVFdfcGlKOE9FcXpNcnMzMzhxb3k3M2xIb1ozM053M3pLcXloU2pWTFUzTV8wUkpWUVpWQ1dsUXhnZV9yRFJsSDlsSVl5U1…
Two muscle-preserving candidates may be tested on mice in space under PMGC's proposal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSmNqeHVRSVNFaE83NXRzZzgtUXd4VHZfLVUydW5VRGhDWFIyRWVmOEFVMXZfM3QxLUtUTGJpbGZxMmlDUXNKT2hwVW5vRERxQ08wVnVKSTFWUGVhWWxvZlc4cEV6ekVjMUdKTk1YbUZ2eXYtOEdRQWU3S0JuMEpUVGR3MHlXRnI1bFF4dX…
PMGC Holdings Inc. Announces 1-for-10 Reverse Stock Split Effective August 21, 2026 | ELAB Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOaWJIMnJNeURiZmMwVDh3NFRGNDhQZU1Vd0VFZzJLa2RPRzEwM0NNdGp4eVBIUzBPNXQxcWlRdERiUmhySTFwSzg0TEV1QjA5aG8zQ05kRl82Z3k3TWFKYnVGbGlKeVpaUDVNSm42T1duTWRZcVgzUm9WeWRkM1lZTjllcndlbEhFeS1JQj…
ELAB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9BaU5PcTRmclhCNXJpaDlsTUJjci1iLUREUkw3aGZ1OEdqRS1uTm9YMEc3TDVvcUdIbHlFa0VFS01Gc2lpZ1E?oc=5" target="_blank">ELAB</a> <font color="#6f6f6f">Finviz</font>…
ELAB — Frequently Asked Questions
What is the current share price of PMGC Holdings Inc. (ELAB)?
As of 2026-09-19 21:16 PDT, PMGC Holdings Inc. (ELAB) trades at $4.85 on NasdaqCM. Its 52-week range is $4.85 to $2,167.20.
What is the market capitalisation of ELAB?
PMGC Holdings Inc. (ELAB) has a market capitalisation of $3.93M on NasdaqCM.
What is the return on equity (ROE) of ELAB?
ELAB has a return on equity (ROE) of -105.22%.
Is ELAB a good stock to buy?
This page provides a data-driven analysis of PMGC Holdings Inc. (ELAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.